Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)

Revenue by Product

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012	Mar 31, 2011	Mar 31, 2010	Mar 31, 2009	Mar 31, 2008	Mar 31, 2007	Mar 31, 2006	Mar 31, 2005
Contract Research Organization	31.51B
Contract Research Organization Growth	22.81%
Medipolis	470.40M
Medipolis Growth	-1.50%
Translational Research	54.16M
Translational Research Growth	364.10%
United States Real Estate	45.98M
Other	328.74M
Other Growth	9.42%
Other	328.74M
Other Growth	9.42%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017	Mar 31, 2016	Mar 31, 2015	Mar 31, 2014	Mar 31, 2013	Mar 31, 2012	Mar 31, 2011	Mar 31, 2010	Mar 31, 2009	Mar 31, 2008	Mar 31, 2007	Mar 31, 2006	Mar 31, 2005
Other	498.21M
Other Growth	26.70%
Japan	21.52B
Japan Growth	20.84%
United States	6.37B
United States Growth	42.18%
South Korea	4.02B
South Korea Growth	6.79%
Other	498.21M
Other Growth	26.70%